Related Experiment Videos
[Somatostatin receptor scintigraphy]
Karin Rasmussen1, Jørn Theil Nielsen, Michael Rehling
1Arhus Sygehus, Afdeling for Klinisk Fysiologi og Nuklearmedicin, Arhus C. karinr@dadlnet.dk
Ugeskrift for Laeger
|December 13, 2005
Summary
Somatostatin receptor scintigraphy (SRS) effectively visualizes neuroendocrine tumors, especially carcinoids. Further research is needed to establish its value in non-neuroendocrine tumors and explore new diagnostic agents.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiology
Background:
- Somatostatin receptor scintigraphy (SRS) is a key imaging modality.
- It is used for visualizing various neuroendocrine tumors (NETs).
Purpose of the Study:
- To describe the methodology, clinical aspects, and limitations of SRS.
- To discuss the potential of new somatostatin analogues.
Main Methods:
- Utilizes radiolabeled somatostatin analogues for imaging.
- Focuses on the diagnostic capabilities of SRS for NETs.
Main Results:
- High sensitivity for localizing carcinoid tumors.
- Lower sensitivity for other types of neuroendocrine tumors.
- Value in non-neuroendocrine tumors remains undetermined.
Conclusions:
- SRS is valuable for neuroendocrine tumor visualization.
- New diagnostic and therapeutic somatostatin analogues are under development.